cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Amphastar Pharmaceuticals Inc
12 own
26 watching
Current Price
$41
$0.09
(0.22%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,944.09M
52-Week High
52-Week High
67.66000
52-Week Low
52-Week Low
35.62000
Average Volume
Average Volume
0.22M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
95.1793
iconMarket Capitalization2,944.09M
icon52-Week High67.66000
icon52-Week Low35.62000
iconAverage Volume0.22M
iconDividend Yield--
iconP/E Ratio95.1793
What does the Amphastar Pharmaceuticals Inc do?
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. It operates in two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company's product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, which include critical care drugs, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; and procainamide for documented ventricular arrhythmias. In addition, the company manufactures and distributes recombinant human insulin and porcine insulin. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate that is intended to be used for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. The company was established in 1996 and is headquartered in Rancho Cucamonga, California.
Read More
How much money does Amphastar Pharmaceuticals Inc make?
News & Events about Amphastar Pharmaceuticals Inc.
Ticker Report
10 months ago
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH Get Rating) EVP Rong Zhou sold 5,000 shares of the companys stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $51.79, for a total value of $258,950.00. Following the transaction, the ...
Zolmax
10 months ago
Amphastar Pharmaceuticals (NASDAQ:AMPH Get Rating) and Crinetics Pharmaceuticals (NASDAQ:CRNX Get Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, ...
Ticker Report
11 months ago
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH Get Rating) was the target of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 1,440,000 shares, an increase of 9.9% from the March 31st total of 1,310,000 shares. Approximately 4...
Accesswire
1 year ago
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 24, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will provide a Business update and hold a Conference call today, Monday, April 24, 2023, at 6:00 am Pacific Time.To access the conference call, please dial 877-407-0989, or...
Zolmax
1 year ago
StockNews.com upgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH Get Rating) from a buy rating to a strong-buy rating in a research report report published on Tuesday . Amphastar Pharmaceuticals Stock Down 0.2 % AMPH stock opened at $35.36 on Tuesday. The firm has a 50-day moving average ...
Frequently Asked Questions
Frequently Asked Questions
What is Amphastar Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Amphastar Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Amphastar Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Amphastar Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Amphastar Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Amphastar Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Amphastar Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Amphastar Pharmaceuticals Inc?
plus_minus_icon
What percentage is Amphastar Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Amphastar Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$41
$0.09
(0.22%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00